2 August 2019 - - US-based clinical-stage biotechnology company BioTime, Inc. (NYSE American) (TASE: BTX) is launching a new corporate brand, including a change of its corporate name to Lineage Cell Therapeutics, Inc., effective August 12, 2019, the company said.

In connection with the launch, the company's NYSE American ticker symbol will change to "LCTX" and will be effective at the open of the market on August 12, 2019.

The company's former ticker symbol "BTX" will remain effective through market close as of August 9, 2019. The new website for Lineage Cell Therapeutics will be www.lineagecell.com. The company's new identity reflects its commitment to becoming an innovative, leading cell therapy company and highlights its extensive cell therapy platform.

BioTime also will be relocating its corporate headquarters to Carlsbad, California, effective August 12, 2019.

The move to San Diego County will provide the company with proximity to world-leading academic centers, public and private cell therapy peers, and is expected to offer more centralized decision-making, cost-savings, and access to an extensive network of experienced staff.

BioTime is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. BioTime's programmes are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities.

With this platform BioTime develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials.

These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

BioTime's clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.